MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.290
AS - Asia 6.350
EU - Europa 4.389
SA - Sud America 941
AF - Africa 104
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 6
Totale 23.113
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.050
SG - Singapore 2.114
CN - Cina 1.638
IT - Italia 1.060
GB - Regno Unito 944
BR - Brasile 721
HK - Hong Kong 716
VN - Vietnam 638
FI - Finlandia 489
SE - Svezia 391
DE - Germania 386
BD - Bangladesh 375
RU - Federazione Russa 245
FR - Francia 235
KR - Corea 197
UA - Ucraina 147
TR - Turchia 135
CA - Canada 106
NL - Olanda 102
IN - India 95
BG - Bulgaria 89
AR - Argentina 85
ID - Indonesia 85
JP - Giappone 70
MX - Messico 58
AT - Austria 56
IQ - Iraq 54
AE - Emirati Arabi Uniti 36
ES - Italia 34
PL - Polonia 33
EC - Ecuador 31
AU - Australia 30
ZA - Sudafrica 30
IE - Irlanda 29
PK - Pakistan 29
CL - Cile 26
LT - Lituania 23
MA - Marocco 23
VE - Venezuela 22
CO - Colombia 21
BZ - Belize 20
BE - Belgio 18
UZ - Uzbekistan 18
PH - Filippine 16
CH - Svizzera 14
KW - Kuwait 14
PT - Portogallo 14
TH - Thailandia 14
CZ - Repubblica Ceca 13
MY - Malesia 13
NP - Nepal 13
PE - Perù 13
HU - Ungheria 12
TW - Taiwan 12
GR - Grecia 11
SA - Arabia Saudita 11
DZ - Algeria 10
DO - Repubblica Dominicana 9
KE - Kenya 9
AZ - Azerbaigian 8
CR - Costa Rica 8
KG - Kirghizistan 8
PY - Paraguay 8
EG - Egitto 7
GT - Guatemala 7
UY - Uruguay 7
AL - Albania 6
IL - Israele 6
JM - Giamaica 6
JO - Giordania 6
PR - Porto Rico 6
RO - Romania 6
TN - Tunisia 6
EE - Estonia 5
EU - Europa 5
LV - Lettonia 5
IR - Iran 4
SN - Senegal 4
SV - El Salvador 4
BO - Bolivia 3
BY - Bielorussia 3
DK - Danimarca 3
GY - Guiana 3
KH - Cambogia 3
LB - Libano 3
MT - Malta 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
OM - Oman 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BS - Bahamas 2
CI - Costa d'Avorio 2
CU - Cuba 2
ET - Etiopia 2
KY - Cayman, isole 2
Totale 23.077
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.557
Singapore 1.268
Ashburn 1.150
Fairfield 1.026
Hong Kong 707
Hefei 586
San Jose 583
Woodbridge 574
Houston 471
Southend 461
Seattle 445
Chandler 438
Helsinki 433
Wilmington 325
Cambridge 306
London 293
Beijing 268
Ann Arbor 255
New York 237
Nyköping 235
Ho Chi Minh City 226
Jacksonville 211
The Dalles 209
Council Bluffs 207
Dearborn 193
Seoul 193
Los Angeles 183
Modena 181
Munich 146
Hanoi 137
Milan 122
Dallas 115
Lauterbourg 113
Chicago 108
San Diego 103
Moscow 98
Buffalo 91
Princeton 78
Sofia 78
São Paulo 71
Shanghai 63
Jakarta 54
Eugene 51
Boardman 46
Bologna 46
Salt Lake City 42
Tokyo 40
Columbus 39
Nuremberg 39
Rome 38
Izmir 37
Redondo Beach 37
Amsterdam 36
Orem 35
Rio de Janeiro 35
Kent 34
Frankfurt am Main 30
Haiphong 30
Redwood City 29
Dublin 27
Toronto 27
Atlanta 25
Brooklyn 25
Florence 25
Da Nang 24
Elk Grove Village 24
Guangzhou 22
Mexico City 22
North Bergen 22
Reggio Emilia 22
Montreal 21
Belize City 20
Vienna 20
Johannesburg 19
Lappeenranta 19
Naples 19
Brasília 18
Denver 18
Phoenix 18
Brussels 17
Chennai 17
Baghdad 16
Las Vegas 16
Miano 16
Palermo 16
Tashkent 16
Waltham 16
Warsaw 16
Ankara 15
Kilburn 15
Mumbai 15
Portsmouth 15
Quito 15
Kuwait City 14
Delft 13
Falls Church 13
Hyderabad 13
Paris 13
Parma 13
Porto Alegre 13
Totale 15.992
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 359
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 342
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 337
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 313
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 313
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 299
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 294
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 290
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 289
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 285
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 283
Biotherapies in large vessel vasculitis 279
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 278
Imaging of vasculitis: State of the art 277
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 275
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 275
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 270
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 268
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 267
Biologics in vasculitides: Where do we stand, where do we go from now? 263
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 259
Increased expression of interleukin-22 in patients with giant cell arteritis 255
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 252
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 249
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 248
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 243
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 242
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 239
Updates on the diagnosis and monitoring of giant cell arteritis 237
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 235
Tocilizumab for the treatment of giant cell arteritis 233
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 232
Statin use in giant cell arteritis: a retrospective study 231
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 230
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 228
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 228
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 226
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 222
Large-vessel giant cell arteritis: a cohort study 221
Mycophenolate mofetil in primary central nervous system vasculitis 221
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 221
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 218
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 214
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 214
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 213
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 212
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 201
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 199
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 199
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 198
Giant Cell Arteritis and Polymyalgia Rheumatica 197
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 197
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 193
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 192
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 191
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 187
L30. Assessment of vasculitis extent and severity 187
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 187
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 186
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 185
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 185
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 184
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 183
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 182
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 177
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 173
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 172
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 172
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 171
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 170
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 166
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 164
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 164
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 163
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 163
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 162
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 162
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 159
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 155
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 155
Development of the Takayasu Arteritis Integrated Disease Activity Index 153
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 153
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 150
What to Know About Biopsy Sampling and Pathology in Vasculitis? 149
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 149
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 149
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 148
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 147
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 147
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 144
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 143
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 142
Eosinophilic giant cell arteritis: A different subset of disease? 141
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 138
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 137
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 137
Role of miR-146a and miR-146b in Giant Cell Arteritis. 136
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 136
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 135
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 134
Totale 20.828
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.791
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.390 77 95 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20255.015 138 48 78 342 1.060 826 408 223 534 326 508 524
2025/20269.044 652 414 774 873 960 612 1.203 451 955 684 798 668
2026/2027306 306 0 0 0 0 0 0 0 0 0 0 0
Totale 23.333